127285-08-9

Usage

Uses

Used in Pharmaceutical Industry:
1-Isopropyl-piperidin-4-ylamine is used as an intermediate in the synthesis of antihistamines and analgesics for their therapeutic effects in treating allergies and pain relief, respectively. Its structural properties allow for the creation of compounds that can effectively target histamine receptors and modulate pain pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Isopropyl-piperidin-4-ylamine is utilized as a precursor in the development of pesticides and other crop protection agents, contributing to enhanced agricultural productivity and crop protection.
Used as a Corrosion Inhibitor:
1-Isopropyl-piperidin-4-ylamine is employed as a corrosion inhibitor in various industrial applications, particularly in the protection of metal surfaces from degradation due to environmental factors, thereby extending the service life of equipment and structures.
Used as a Polymerization Inhibitor:
1-ISOPROPYL-PIPERIDIN-4-YLAMINE also serves as a polymerization inhibitor, preventing unwanted reactions in the production of polymers, ensuring the quality and consistency of the final product.
Used in Specialty Chemicals Synthesis:
1-Isopropyl-piperidin-4-ylamine is used in the synthesis of specialty chemicals, where its unique chemical properties contribute to the development of niche products with specific applications in various industries.
Safety Note:
Due to its flammable nature, 1-Isopropyl-piperidin-4-ylamine requires careful handling and storage, adhering to proper safety protocols to prevent accidents and ensure the well-being of personnel and the integrity of the environment.

InChI:InChI=1/C8H18N2/c1-7(2)10-5-3-8(9)4-6-10/h7-8H,3-6,9H2,1-2H3

Upstream product

• 534595-37-4 (1-isopropylpiperidin-4-yl)carbamic acid tert-butyl ester 
• 182223-54-7 piperidin-4-ylcarbamic acid benzyl ester 
• 87120-72-7 1-(tert-butoxycarbonyl)-4-aminopiperidine 
• 220394-97-8 4-(benzyloxycarbonylamino)-1-(tert-butoxycarbonyl)piperidine 
• 609804-23-1 benzyl (1-iso-propylpiperidin-4-yl)carbamate 
• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 

Downstream Products

• 851120-79-1 (2S,3S)-methyl 4-(1-isopropylpiperidin-4-ylamino)-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate 
• 959242-49-0 N-(1-isopropylpiperidin-4-yl)-2-phenylacetamide 
• 1415678-45-3 C₂₃H₃₁N₅ 
• 1320288-41-2 7-(benzyloxy)-2-cyclohexyl-N-(1-isopropylpiperidin-4-yl)-6-methoxyquinazolin-4-amine 
• 1057855-66-9 N-[2-(1-isopropylpiperidin-4-ylcarbamoyl)benzyl]-5-chlorothiophene-2-carboxamide 
• 1266620-16-9 C₁₆H₂₁ClFN₃O₂ 
• 1229021-41-3 C₂₆H₂₇N₅O₂ 
• 1228943-41-6 4-(1-isopropylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide 
• 1137869-16-9 4-(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-ylamino)-N-(1-isopropyl-piperidin-4-yl)-3-methoxy-benzamide 
• 863484-00-8 5-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-pyrrole-2-carboxylic acid benzyl ester 
• 863484-02-0 4-nitro-1H-pyrrole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide trifluoroacetate 
• 1057214-93-3 5-phenyl-1H-pyrrole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide 

Relevant academic research and scientific papers

Discovery of 2-substituted 1H-benzo[d]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in?vivo anti-tumor activity

Novel 1H-benzo[d]immidazole-4-carboxamide derivatives bearing five-membered or six-membered N-heterocyclic moieties at the 2-position were designed and synthesized as PARP-1 inhibitors. Structure-activity relationships were conducted and led to a number of potent PARP-1 inhibitors having IC50 values in the single or double digit nanomolar level. Some potent PARP-1 inhibitors also had similar inhibitory activities against PARP-2. Among all the synthesized compounds, compound 10a and 11e displayed strong potentiation effects on temozolomide (TMZ) in MX-1?cells (PF50?=?7.10, PF50?=?4.17). In?vivo tumor growth inhibition was investigated using compound 10a in combination with TMZ, and it was demonstrated that compound 10a could strongly potentiate the cytotoxicity of TMZ in MX-1 xenograft tumor model. Two co-crystal structures of compounds 11b and 15e complexed with PARP-1 were achieved and demonstrated a unique binding mode of these benzo-imidazole derivatives.

2-Aminomethylphenylamine as a novel scaffold for factor Xa inhibitor

We have been researching orally active factor Xa inhibitor for a long time. We explored the new diamine linker using effective ligands to obtain a new attractive original scaffold 2-aminomethylphenylamine derivative. Compound 1D showed very strong in vitro and in vivo factor Xa inhibitory activity, as well as favorable PK profiles in po administration to monkeys.

TROPANE COMPOUNDS

A compound according to Formula I or II: (I) or (II) wherein R1, R1b, R2, L1, and L2 and L2b are as defined in the specification, pharmaceutical compositions thereof, and methods of use thereof.

NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention discloses novel naphthalenyloxypropenyl derivatives useful for inhibiting the enzyme activity of histone deacetylase, leading effective suppression of cancer cell proliferation

ALKYLCARBAMOYL NAPHTHALENYLOXY- OCTENOYLHYDROXYAMIDE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PREPARATION THEREOF

This invention discloses a novel alkylcarbamoyl naphthalenyloxy octenoylhydroxyamide derivative of formula (1) useful for inhibiting the enzyme activity of histone deacetylase, which leads to effective suppression of the cancer cell proliferation, a method for preparing same and a pharmaceutical composition comprising same.

Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: A study combining structure-activity relationship and X-ray crystallography

Structure-activity relationships within a series of highly potent 2-carboxyindole-based factor Xa inhibitors incorporating a neutral P1 ligand are described with particular emphasis on the structural requirements for addressing subpockets of the factor Xa enzyme. Interactions with the subpockets were probed by systematic substitution of the 2-carboxyindole scaffold, in combination with privileged P1 and P4 substituents. Combining the most favorable substituents at the indole nucleus led to the discovery of a remarkably potent factor Xa inhibitor displaying a Ki value of 0.07 nM. X-ray crystallography of inhibitors bound to factor Xa revealed substituent-dependent switching of the inhibitor binding mode and provided a rationale for the SAR obtained. These results underscore the key role played by the P1 ligand not only in determining the binding affinity of the inhibitor by direct interaction but also in modifying the binding mode of the whole scaffold, resulting in a nonlinear SAR.

Indole derivatives as factor Xa inhibitors

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.

Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents

A series of novel, highly potent 2-carboxyindole-based factor Xa inhibitors is described. Structural requirements for neutral ligands, which bind in the S1 pocket of factor Xa were investigated with the 2-carboxyindole scaffold. This privileged fragment assembly approach yielded a set of equipotent, selective inhibitors with structurally diverse neutral P1 substituents.

Pyrazole-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formula I, in which R0 ; R1 ; R2 ; R3 ; R4; Q; V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

BENZOFURAN DERIVATIVE

The present invention provides a benzofuran derivative of the formula [1]: wherein x is a group of the formula: -N="or" -CH=; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the chain, or an oxygen atom; R1 is a hydrogen atom or a halogen atom; Ring B is an optionally substituted benzene ring; and R3 is a hydrogen atom, or a pharmaceutically acceptable salt thereof, which is useful as a medicament, especially as an activated blood coagulation factor X inhibitor.